Biocon Biologics
- All
- News
- Videos
-
Centre Gives Sanction To Prosecute Joint Drugs Controller In Bribery Case
The government has granted the sanction to prosecute Central Drugs Standard Control Organisation's joint drugs controller S Eswara Reddy, clearing the decks for initiating a trial against him for allegedly taking a bribe to favourably recommend Biocon Biologics' insulin injection, officials said Sunday.
-
Biocon Biologics Promotes Shreehas Tambe As The Chief
Shreehas Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said
-
CBI Files Charge Sheet In Rs 9 lakh Biocon Bribery Case, 5 Named
The CBI has filed a charge sheet against five persons, including a Joint Drug Controller of the Central Drugs Standard Control Organisation(CDSCO) and a Biocon Biologics executive, in a Rs nine lakh bribery case.
-
Biocon Biologics Denies Bribery Charge, Says Followed Regulations
Biocon Biologics has denied allegations of bribery against the company and its officials regarding approval for one of its products in India
-
Biocon's March Quarter Profit Falls 4% To Rs 283 Crore
Biocon Ltd on Thursday reported a 4 per cent decline in consolidated net profit to Rs 283.9 crore in the fourth quarter ended on March 31, 2022
-
Biocon Biologics' IPO Within Next 2 Years, Says Kiran Mazumdar-Shaw
Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within the next two years, Kiran Mazumdar-Shaw said on Monday.
-
Biocon Says Clinical Study For Drug Itolizumab Initiated After Drug Regulator's Approval
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C
-
Biocon Gains After Arm Enters Strategic Alliance With Serum Institute
Biocon Biologics will offer approximately 15 per cent stake to SILS, at a valuation of $4.9 billion.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Subsidiary Receives Nod To Use Cytosorb In Covid-19 Treatment
The licence will be effective until the COVID-19 outbreak is controlled in the country, the company said in a regulatory filing.
-
Biocon Posts 17% Rise In Q1 Profit
Biotechnology major Biocon on Thursday posted a 17 per cent rise in net profit at Rs 147 crore for the fiscal first quarter that ended on June 30, 2016, on the back of robust growth in segments like biologics and branded formulations.
-
'Walk The Talk', With Kiran Mazumdar Shaw: Full Transcript
This episode of Walk The Talk features Biocon chief Kiran Mazumar Shaw talking about the need to leverage India's strong biology base into innovation.
-
Biocon to Invest 10% of Biopharma Revenues on R&D
The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.
-
Biocon Releases Novel Drug to Treat Skin Disease
India's leading biotech firm Biocon has unveiled a new drug to treat psoriasis, a skin disease that occurs when the immune system mistakes a normal skin cell for a pathogen."Psoriasis is a socially debilitating disease affecting around three percent of...
-
Biocon launches biological drug to combat psoriasis
Alzumab, now commercially available in the country for treating patients with chronic plaque psoriasis, was priced at least 50 per cent lower than similar drugs in the market, the company's chairperson and managing director, Kiran Mazumdar-Shaw told a news conference here.
-
Centre Gives Sanction To Prosecute Joint Drugs Controller In Bribery Case
The government has granted the sanction to prosecute Central Drugs Standard Control Organisation's joint drugs controller S Eswara Reddy, clearing the decks for initiating a trial against him for allegedly taking a bribe to favourably recommend Biocon Biologics' insulin injection, officials said Sunday.
-
Biocon Biologics Promotes Shreehas Tambe As The Chief
Shreehas Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said
-
CBI Files Charge Sheet In Rs 9 lakh Biocon Bribery Case, 5 Named
The CBI has filed a charge sheet against five persons, including a Joint Drug Controller of the Central Drugs Standard Control Organisation(CDSCO) and a Biocon Biologics executive, in a Rs nine lakh bribery case.
-
Biocon Biologics Denies Bribery Charge, Says Followed Regulations
Biocon Biologics has denied allegations of bribery against the company and its officials regarding approval for one of its products in India
-
Biocon's March Quarter Profit Falls 4% To Rs 283 Crore
Biocon Ltd on Thursday reported a 4 per cent decline in consolidated net profit to Rs 283.9 crore in the fourth quarter ended on March 31, 2022
-
Biocon Biologics' IPO Within Next 2 Years, Says Kiran Mazumdar-Shaw
Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within the next two years, Kiran Mazumdar-Shaw said on Monday.
-
Biocon Says Clinical Study For Drug Itolizumab Initiated After Drug Regulator's Approval
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C
-
Biocon Gains After Arm Enters Strategic Alliance With Serum Institute
Biocon Biologics will offer approximately 15 per cent stake to SILS, at a valuation of $4.9 billion.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Subsidiary Receives Nod To Use Cytosorb In Covid-19 Treatment
The licence will be effective until the COVID-19 outbreak is controlled in the country, the company said in a regulatory filing.
-
Biocon Posts 17% Rise In Q1 Profit
Biotechnology major Biocon on Thursday posted a 17 per cent rise in net profit at Rs 147 crore for the fiscal first quarter that ended on June 30, 2016, on the back of robust growth in segments like biologics and branded formulations.
-
'Walk The Talk', With Kiran Mazumdar Shaw: Full Transcript
This episode of Walk The Talk features Biocon chief Kiran Mazumar Shaw talking about the need to leverage India's strong biology base into innovation.
-
Biocon to Invest 10% of Biopharma Revenues on R&D
The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.
-
Biocon Releases Novel Drug to Treat Skin Disease
India's leading biotech firm Biocon has unveiled a new drug to treat psoriasis, a skin disease that occurs when the immune system mistakes a normal skin cell for a pathogen."Psoriasis is a socially debilitating disease affecting around three percent of...
-
Biocon launches biological drug to combat psoriasis
Alzumab, now commercially available in the country for treating patients with chronic plaque psoriasis, was priced at least 50 per cent lower than similar drugs in the market, the company's chairperson and managing director, Kiran Mazumdar-Shaw told a news conference here.
